User profiles for Antonio Ramos-Martínez
 | Antonio Ramos-MartinezHospital Universitario Puerta de Hierro-Majadahonda Verified email at salud.madrid.org Cited by 8241 |
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia
C Avendaño-Solá, A Ramos-Martínez… - The Journal of …, 2021 - Am Soc Clin Investig
BACKGROUND Passive immunotherapy with convalescent plasma (CP) is a potential
treatment for COVID-19. Evidence from controlled clinical trials is inconclusive. METHODS We …
treatment for COVID-19. Evidence from controlled clinical trials is inconclusive. METHODS We …
[HTML][HTML] Epidemiología y clínica de las infecciones y colonizaciones causadas por enterobacterias productoras de carbapenemasas en un hospital de tercer nivel
…, Á Asensio-Vegas, A Ramos-Martínez - Revista Española de …, 2020 - ncbi.nlm.nih.gov
… Ilduara Pintos-Pascual, 1 Mireia Cantero-Caballero, 2 Elena Muñez Rubio, 1 Isabel
Sánchez-Romero, 3 Ángel Asensio-Vegas, 2 and Antonio Ramos-Martínez 1 …
Sánchez-Romero, 3 Ángel Asensio-Vegas, 2 and Antonio Ramos-Martínez 1 …
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
P Domingo, I Mur, GM Mateo, M del Mar Gutierrez… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID
…, AD Bendala-Estrada, A Ramos-Martínez… - PloS one, 2021 - journals.plos.org
Background Most patients with COVID-19 receive antibiotics despite the fact that bacterial co-infections
are rare. This can lead to increased complications, including antibacterial …
are rare. This can lead to increased complications, including antibacterial …
Convalescent plasma for COVID-19: a multicenter, randomized clinical trial
C Avendano-Sola, A Ramos-Martinez, E Munez-Rubio… - MedRxiv, 2020 - medrxiv.org
Background Passive immunotherapy with convalescent plasma (CP) is a potential treatment
for COVID-19 for which evidence from controlled clinical trials is lacking. Methods We …
for COVID-19 for which evidence from controlled clinical trials is lacking. Methods We …
A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality
…, A Callejas-Díaz, A Ramos-Martínez… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Evidence to support the use of steroids in coronavirus disease 2019 (COVID-19) pneumonia
is lacking. We aim to determine the impact of steroid use for COVID-19 pneumonia on …
is lacking. We aim to determine the impact of steroid use for COVID-19 pneumonia on …
Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy
…, A Muiño Míguez, A Ramos Martínez… - BMC infectious …, 2021 - Springer
Background Since December 2019, the COVID-19 pandemic has changed the concept of
medicine. This work aims to analyze the use of antibiotics in patients admitted to the hospital …
medicine. This work aims to analyze the use of antibiotics in patients admitted to the hospital …
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 …
Background Rezafungin is a next-generation, once-a-week echinocandin in development
for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive …
for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive …
Hospital readmissions of discharged patients with COVID-19
…, A Fermández-Cruz, A Ramos-Martinez… - … Journal of General …, 2020 - Taylor & Francis
Objective To analyse the rate of occurrence and the clinical variables associated with
readmission of patients who had previously been discharged after admission for COVID-19. …
readmission of patients who had previously been discharged after admission for COVID-19. …
Incidence, clinical presentation, relapses and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 …
…, M Valle-Falcones, A Ramos-Martínez - Clinical Infectious …, 2022 - academic.oup.com
Background Our objective is to describe the presentation and complications, including
relapses, of coronavirus disease 2019 (COVID-19) in patients under anti-CD20 treatments. In …
relapses, of coronavirus disease 2019 (COVID-19) in patients under anti-CD20 treatments. In …
